FrancophonIA/ELRC3.0 huggingface dataset:
English: Pharmacokinetic studies have not been performed with emtricitabine or tenofovir (administered as tenofovir disoproxil) in the elderly (over 65 years of age).
Danish: Der er ikke foretaget farmakokinetiske studier med emtricitabin eller tenofovir (administreret som tenofovirdisoproxil) hos ældre (over 65 år).
English: Limited pharmacokinetic data are available for emtricitabine and tenofovir after co-administration of separate preparations or as a fixed-dose combination in patients with renal impairment.
Danish: Der foreligger begrænsede farmakokinetiske data for emtricitabin og tenofovir efter samtidig indgivelse i form af separate præparater eller i form af en kombination i fast dosering hos patienter med nedsat nyrefunktion.
English: Co-administration of tenofovir disoproxil and didanosine at a dose of 400 mg daily has been associated with a significant decrease in CD4 cell count, possibly due to an intracellular interaction increasing phosphorylated (i.e. active) didanosine.
Danish: Samtidig administration af tenofovirdisoproxil og didanosin ved en dosis på 400 mg dagligt er blevet forbundet med et signifikant fald i CD4-celletallet, muligvis på grund af en intracellulær interaktion, som øgede fosforyleret (dvs. aktiv) didanosin.
English: Emtricitabine/tenofovir disoproxil should only be used to reduce the risk of acquiring HIV-1 in individuals confirmed to be HIV negative (see section 4.3).
Danish: Emtricitabin/tenofovirdisoproxil bør kun anvendes til at mindske risikoen for at få HIV 1 hos personer, der bekræftes at være HIV-negative (se pkt.
English: When missing data were excluded, 91% of patients in the tenofovir disoproxil treatment group and 94% of patients in the stavudine or zidovudine treatment group had HIV 1 RNA concentrations < 400 copies/mL at week 48.
Danish: Når manglende data fraregnes, havde 91 % af patienterne i gruppen, der fik tenofovirdisoproxil, og 94 % af patienterne i gruppen, der fik stavudin eller zidovudin, koncentrationer af HIV 1-rna på < 400 kopier/ml i uge 48.
English: One tenofovir disoproxil treated subject and no stavudine or zidovudine treated subjects experienced significant (> 4%) lumbar spine BMD loss at week 48.
Danish: En forsøgsperson, der fik tenofovirdisoproxil, og ingen forsøgspersoner, der fik stavudin eller zidovudin, havde signifikant fald (> 4 %) i BMD i lænderygsøjlen i uge 48.
English: PrEP educational brochure for the individual at risk (to be provided by healthcare provider [HCP]):
Danish: PrEP-undervisningsbrochure for den udsatte person (skal udleveres af læge/sundhedspersonale):
English: Moderate renal impairment (CrCl 30-49 mL/min)
Danish: Moderat nedsat nyrefunktion (CrCl 30-49 ml/min)
English: Emtricitabine and tenofovir are primarily excreted by the kidneys by a combination of glomerular filtration and active tubular secretion.
Danish: Emtricitabin og tenofovir udskilles renalt ved en kombination af glomerulær filtrering og aktiv tubulær sekretion.
English: Prior to initiating Emtricitabine/Tenofovir disoproxil Mylan for the treatment of HIV-1 infection or for use in pre-exposure prophylaxis, it is recommended that creatinine clearance is calculated in all individuals.
Danish: Inden påbegyndelse af Emtricitabine/Tenofovir disoproxil Mylan til behandling af HIV 1-infektion eller til brug som profylakse før eksponering anbefales det at beregne kreatininclearance hos alle personer.
English: Assessment of adverse reactions related to emtricitabine is based on experience in three paediatric studies (n = 169) where treatment-naïve (n = 123) and treatment-experienced (n = 46) paediatric HIV infected patients aged 4 months to 18 years were treated with emtricitabine in combination with other antiretroviral agents.
Danish: Vurderingen af bivirkninger i forbindelse med emtricitabin er baseret på erfaringer fra tre pædiatriske studier (n = 169), hvor behandlingsnaive (n = 123) og behandlingserfarne (n = 46) pædiatriske HIVinficerede patienter i alderen 4 måneder til 18 år blev behandlet med emtricitabin i kombination med andre antiretrovirale stoffer.
English: The 48-week primary endpoint data showed that the combination of emtricitabine, tenofovir disoproxil and efavirenz provided superior antiviral efficacy as compared with the fixed combination of lamivudine and zidovudine with efavirenz as shown in Table 4.
Danish: En sammenligning af de primære endepunkter-data fra uge 48 viste, at kombinationen af emtricitabin, tenofovirdisoproxil og efavirenz gav bedre antiviral virkning end kombinationsformuleringen med lamivudin og zidovudin og efavirenz.
English: Pharmacokinetic parameters were mainly determined following administration of single doses of emtricitabine 200 mg or tenofovir disoproxil 245 mg to non-HIV infected subjects with varying degrees of renal impairment.
Danish: Farmakokinetiske parametre blev hovedsageligt bestemt efter indgivelse af enkelte doser 200 mg emtricitabin eller 245 mg tenofovirdisoproxil til ikke-HIV-inficerede forsøgspersoner med forskellige grader af nedsat nyrefunktion.
English: PrEP educational brochure for prescribers:
Danish: PrEP-undervisningsbrochure til ordinerende læger:
English: Moreover, the reversibility of renal toxicity after cessation of tenofovir disoproxil for the treatment of HIV-1 infection or after cessation of emtricitabine/tenofovir disoproxil for pre-exposure prophylaxis cannot be fully ascertained.
Danish: Reversibiliteten af nefrotoksicitet efter afbrydelse af tenofovirdisoproxil i behandlingen af HIV 1, eller efter afbrydelse af Emtricitabine/Tenofovir disoproxil Mylan ved profylakse før eksponering, kan desuden ikke fastlægges fuldt ud.
English: Pharmacokinetic studies have not been performed with emtricitabine/tenofovir disoproxil in children and adolescents (under 18 years of age).
Danish: Der er ikke udført farmakokinetiske studier med emtricitabin/tenofovirdisoproxil hos børn og unge (under 18 år).
English: Rarely, pancreatitis and lactic acidosis, sometimes fatal, have been reported.
Danish: I sjældne tilfælde er der rapporteret pancreatitis og laktatacidose, undertiden med dødelig udgang.
English: * Patients receiving emtricitabine, tenofovir disoproxil and efavirenz were given emtricitabine/tenofovir disoproxil plus efavirenz from week 96 to 144.
Danish: * Patienter, som fik emtricitabin, tenofovirdisoproxil og efavirenz, fik emtricitabin/tenofovirdisoproxil plus efavirenz fra uge 96 til 144.
English: Emtricitabine and tenofovir are phosphorylated by cellular enzymes to form emtricitabine triphosphate and tenofovir diphosphate, respectively.
Danish: Emtricitabin og tenofovir fosforyleres af celleenzymer til at danne henholdsvis emtricitabintriphosphat og tenofovirdiphosphat.
English: • Emtricitabine/Tenofovir disoproxil Mylan is used to treat Human Immunodeficiency Virus 1 (HIV-1) infection in adults.
Danish: • Emtricitabine/Tenofovir disoproxil Mylan bruges til at behandle infektion forårsaget af humant immundefektvirus 1 (HIV 1-infektion) hos voksne.
English: Danmark BGP Products ApS Tlf: + 46 28116932
Danish: Danmark BGP Products ApS Tlf: + 46 28116932 (Sverige)
English: A higher risk of renal impairment has been reported in HIV-1 infected patients receiving tenofovir disoproxil in combination with a ritonavir or cobicistat boosted protease inhibitor.
Danish: Der er rapporteret en højere risiko for nedsat nyrefunktion hos HIV 1-inficerede patienter, der fik tenofovirdisoproxil i kombination med en ritonavir- eller cobicistat-boostet proteasehæmmer.
English: - Emtricitabine/Tenofovir disoproxil Mylan should always be used combined with other medicines to treat HIV infection.
Danish: Emtricitabine/Tenofovir disoproxil Mylan skal altid anvendes sammen med anden medicin til behandling af HIV-infektion.
English: Medis International a.s vyrobani zavod Bolatice,Prumyslova, -961/16, Bolatice 747 23, Czech Republic
Danish: Medis International a.s vyrobani zavod Bolatice, Prumyslova, -961/16, Bolatice
English: Taking Emtricitabine/Tenofovir disoproxil Mylan with other medicines containing didanosine (for treatment of HIV infection): Taking emtricitabine/tenofovir disoproxil with other antiviral medicines that contain didanosine can raise the levels of didanosine in your blood and may reduce CD4 cell counts.
Danish: Indtagelse af Emtricitabine/Tenofovir disoproxil Mylan sammen med medicin som indeholder didanosin (til behandling af HIV-infektion): Hvis De tager emtricitabin/tenofovirdisoproxil sammen med antiviral medicin, som indeholder didanosin, kan det øge indholdet af didanosin i blodet og reducere CD4-celletallet.
English: Age (Yrs), Mean (SD) Race, N (%) Black/African American White Mixed/Other Asian Hispanic/Latino Ethnicity, N (%) Sexual Risk Factors at Screening
Danish: Spansk/latinamerikansk etnicitet, N (%) Seksuelle risikofaktorer ved screening
English: METHOD AND ROUTE OF ADMINISTRATION Oral use
Danish: ANVENDELSESMÅDE OG ADMINISTRATIONSVEJ Oral anvendelse.
English: Treatment of HIV-1 infection:
Danish: Behandling af HIV 1-infektion:
English: The pharmacokinetics of tenofovir (administered as tenofovir disoproxil) have not been specifically studied in different ethnic groups.
Danish: Tenofovirs (administreret som tenofovirdisoproxil) farmakokinetik er ikke blevet specifikt undersøgt hos forskellige etniske grupper.
English: Severe renal impairment (CrCl <30 mL/min) and haemodialysis patients
Danish: Svært nedsat nyrefunktion (CrCl <30 ml/min) og hæmodialysepatienter
English: HIV-1 RNA < 50 copies/mL (TLOVR) p-value % difference (95%CI)
Danish: HIV 1-rna < 50 kopier /ml (TLOVR) p-værdi % forskel (95%CI)
English: HIV-1 infected patients with chronic hepatitis B or C treated with antiretroviral therapy are at an increased risk for severe and potentially fatal hepatic adverse reactions.
Danish: HIV 1-inficerede patienter med kronisk hepatitis B eller C behandlet med antiretroviral behandling har øget risiko for alvorlige og potentielt dødelige hepatiske bivirkninger.
English: Based on minimal hepatic metabolism and the renal route of elimination for emtricitabine, it is unlikely that a dose adjustment would be required for emtricitabine/tenofovir disoproxil in patients with hepatic impairment (see sections 4.2 and 5.2).
Danish: På grund af minimal hepatisk metabolisme og den renale eliminationsvej for emtricitabin er det usandsynligt, at dosisjustering af emtricitabin/tenofovirdisoproxil er nødvendig hos patienter med nedsat leverfunktion (se pkt.
English: 9% (2% to 17%)
Danish: 9% (2% til 17%)
English: The K65R mutation can also be selected by abacavir or didanosine and results in reduced susceptibility to these agents plus lamivudine, emtricitabine and tenofovir.
Danish: K65R-mutationen kan desuden udsøges ved hjælp af abacavir eller didanosin og forårsager nedsat følsomhed over for disse stoffer samt lamivudin, emtricitabin og tenofovir.
English: As a general rule, it is recommended that HIV infected women do not breast-feed their infants under any circumstances in order to avoid transmission of HIV to the infant.
Danish: For at undgå overførsel af HIV til spædbørn anbefales det generelt, at HIV-inficerede kvinder under ingen omstændigheder ammer deres børn.
English: • Whenever possible, Emtricitabine/Tenofovir disoproxil Mylan should be taken with food.
Danish: • Emtricitabine/Tenofovir disoproxil Mylan skal så vidt muligt tages sammen med mad.
English: • pentamidine (for infections)
Danish: • pentamidin (mod infektioner)
English: The use of emtricitabine/tenofovir disoproxil is not recommended in patients with severe renal impairment (creatinine clearance < 30 mL/min) and in patients who require haemodialysis since appropriate dose reductions cannot be achieved with the combination tablet (see sections 4.2 and 5.2).
Danish: Emtricitabin/tenofovirdisoproxil anbefales ikke til patienter med svært nedsat nyrefunktion (kreatininclearance < 30 ml/min) og hos patienter, som skal have hæmodialyse, da de nødvendige dosisreduktioner ikke kan opnås med kombinationstabletten (se pkt.
English: Patients with rare hereditary problems of galactose intolerance, total lactase deficiency, or glucose-galactose malabsorption should not take this medicinal product.
Danish: Dette lægemiddel bør ikke anvendes til patienter med hereditær galactoseintolerans, total lactasemangel eller glucose/galactosemalabsorption.
English: The safety and efficacy of emtricitabine/tenofovir disoproxil have not been established in patients with significant underlying liver disorders.
Danish: Emtricitabin/tenofovirdisoproxils sikkerhed og virkning er ikke blevet fastslået hos patienter med signifikante underliggende leversygdomme.
English: Didanosine/Emtricitabine
Danish: Didanosin/Emtricitabin
English: At 48 weeks, 70% and 64% of patients demonstrated HIV-1 RNA < 50 copies/mL with the once and twice daily regimens of lopinavir/ritonavir, respectively.
Danish: I uge 48 af behandlingen udviste 70% og 64% af patienterne HIV 1-rna < 50 kopier/ml med henholdsvis en og to gange daglig behandling med lopinavir/ritonavir.
English: • Any signs of inflammation or infection.
Danish: • Tegn på inflammation (en betændelseslignende reaktion) eller infektion.
English: INFORMATION IN BRAILLE Emtricitabine/Tenofovir disoproxil Mylan 17.
Danish: INFORMATION I BRAILLESKRIFT Emtricitabine/Tenofovir disoproxil Mylan 17.
English: HIV-1 RNA < 400 copies/mL (TLOVR) p-value % difference (95%CI)
Danish: HIV 1-rna < 400 kopier/ml (TLOVR) p-værdi % forskel (95%CI)
English: 13% (4% to 22%)
Danish: 13% (4% til 22%)
English: • amphotericin B (for fungal infection)
Danish: • amphotericin B (mod svampeinfektion)
English: The safety and efficacy of emtricitabine/tenofovir disoproxil for pre-exposure prophylaxis in patients with HBV or HCV infection has not been established.
Danish: Sikkerheden og virkningen af emtricitabin/tenofovirdisoproxil som proylakse før eksponering hos patienter med HBV- eller HCV-infektion er ikke fastlagt.
English: Relative Risk Reduction (2-sided 95% CI)a
Danish: Relativ Risikoreduktion (2-sidet 95% CI)a
English: Seroconversions / N Relative Risk Reduction (95% CI)b
Danish: Serokonvertering / N Relativ risikoreduktion (95% CI)b
English: Lamivudine+ zidovudine+efavirenz
Danish: Lamivudin+ zidovudin+efavirenz
English: A decreased dosage of 250 mg didanosine co-administered with tenofovir disoproxil therapy has been associated with reports of high rates of virological failure within several tested combinations.
Danish: En reduceret dosis på 250 mg didanosin administreret samtidig med et regime indeholdende tenofovirdisoproxil er blevet forbundet med rapporter om høj forekomst af virologisk svigt i flere testede kombinationer.
English: Renal failure, renal impairment, elevated creatinine, hypophosphataemia and proximal tubulopathy (including Fanconi syndrome) have been reported with the use of tenofovir disoproxil (see section 4.8).
Danish: Nyresvigt, nedsat nyrefunktion, forhøjet kreatinin, hypofosfatæmi og proksimal tubulopati (herunder Fanconis syndrom) er blevet rapporteret ved brug af tenofovirdisoproxil (se pkt.
English: The following may be signs of lactic acidosis:
Danish: Følgende kan være tegn på laktatacidose:
English: In vivo treatment of HIV-1: In an open-label randomised clinical study (GS-01-934) in antiretroviral-naïve patients, genotyping was performed on plasma HIV-1 isolates from all patients with confirmed HIV RNA > 400 copies/mL at weeks 48, 96 or 144 or at the time of early study drug discontinuation.
Danish: In vivo-behandling af HIV 1: I et åbent, randomiseret, klinisk studie (GS-01-934) med antiretroviralnaive patienter blev der foretaget genotypebestemmelser på plasma-HIV 1-isolater fra alle patienter med bekræftet HIV-rna > 400 kopier/ml ved uge 48, 96 eller 144 eller på tidspunktet for tidlig seponering af forsøgsmedicinen.
English: If bone abnormalities are detected or suspected during use of emtricitabine/tenofovir disoproxil in any paediatric patient, consultation with an endocrinologist and/or nephrologist should be obtained.
Danish: Hvis knogleabnormiteter mistænkes eller påvises under brugen af Emtricitabine/Tenofovir disoproxil Mylan hos en pædiatrisk patient, bør der søges råd hos en endokrinolog og/eller en nefrolog.
English: Renal monitoring
Danish: Monitorering af nyrefunktionen
English: Patients infected with HIV who also have liver disease (including chronic hepatitis B or C), who are treated with antiretrovirals, have a higher risk of severe and potentially fatal liver complications.
Danish: Patienter, som er inficeret med HIV og har leversygdom (inklusive kronisk hepatitis B eller C), og som behandles med antiretrovirale midler, har en forhøjet risiko for alvorlige og potentielt livstruende bivirkninger i leveren.
English: Consideration should be given to interrupting treatment with emtricitabine/tenofovir disoproxil in patients with creatinine clearance decreased to < 50 mL/min or decreases in serum phosphate to < 1.0 mg/dL (0.32 mmol/L).
Danish: Det bør overvejes at afbryde behandlingen med emtricitabin/tenofovirdisoproxil hos patienter, hvor kreatininclearance falder til < 50 ml/min eller serumphosphat til < 1,0 mg/dl (0,32 mmol/l).
English: Animal studies on emtricitabine and tenofovir disoproxil do not indicate reproductive toxicity (see section 5.3).
Danish: Dyreforsøg med emtricitabin og tenofovirdisoproxil indikerer ikke reproduktionstoksicitet (se pkt.
English: Five subjects (5.6%) had laboratory findings clinically consistent with proximal renal tubulopathy, 4 of whom discontinued tenofovir disoproxil therapy.
Danish: Fem forsøgsdeltagere (5,6 %) havde laboratoriefund, der var klinisk overensstemmende med proksimal renal tubulopati, og 4 af disse seponerede behandlingen med tenofovirdisoproxil.
English: Only Case or Cohort samples from subjects randomised to either tenofovir disoproxil 245 mg or emtricitabine/tenofovir disoproxil were evaluated for detectable plasma tenofovir levels.
Danish: Kun case- eller kohorte-prøver fra forsøgspersoner randomiseret til enten tenofovirdisoproxil 245 mg eller emtricitabin/tenofovirdisoproxil blev vurderet for deterbart plasmaniveau af tenofovir.
English: Number with Tenofovir Detected/ Total Samples (%)
Danish: Antal med detekteret tenofovir/ samlet prøveantal
English: Following oral administration of emtricitabine/tenofovir disoproxil to healthy subjects, emtricitabine and tenofovir disoproxil are rapidly absorbed and tenofovir disoproxil is converted to tenofovir.
Danish: Efter oral indgivelse af emtricitabin/tenofovirdisoproxil hos sunde personer absorberes emtricitabin og tenofovirdisoproxil hurtigt, og tenofovirdisoproxil omdannes til tenofovir.
English: In vivo --pre-exposure prophylaxis: Plasma samples from 2 clinical studies of HIV-1 uninfected subjects, iPrEx and Partners PrEP, were analysed for 4 HIV-1 variants expressing amino acid substitutions (i.e. K65R, K70E, M184V, and M184I) that potentially confer resistance to tenofovir or emtricitabine.
Danish: In vivo- PrEP: Plasmaprøver fra 2 kliniske studier med forsøgspersoner uden HIV-infektion, iPrEx og Partners PrEP, blev analyseret for 4 HIV 1-varianter, der eksprimerer aminosyresubstitutioner (K65R, K70E, M184V og M184I), som potentielt kan udvise resistens over for tenofovir eller emtricitabin.
English: As emtricitabine/tenofovir disoproxil fixed-dose combination tablets contains emtricitabine and tenofovir disoproxil, any interactions that have been identified with these agents individually may occur with the fixed-dose combination.
Danish: Da emtricitabin/tenofovirdisoproxil kombinationstabletter i fast doseringindeholder emtricitabin og tenofovirdisoproxil, kan interaktioner, som er identificeret med disse lægemidler individuelt, forekomme med i kombinationen med fast dosering.
English: Each tablet contains 93.6 mg lactose monohydrate.
Danish: Hjælpestof, som behandleren skal være opmærksom på Hver tablet indeholder 93,6 mg lactosemonohydrat.
English: The pharmacokinetics of tenofovir has been studied in patients with hepatic impairment and no dose adjustment is required.
Danish: Farmakokinetikken af tenofovir er blevet undersøgt hos patienter med nedsat leverfunktion, og dosisjustering er ikke nødvendig.
English: Also contains: lactose monohydrate.
Danish: Indeholder også: lactosemonohydrat.
English: Rarely, inflammation of the pancreas and lactic acidosis (excess lactic acid in the blood), which sometimes causes death, have been reported when medicines containing tenofovir disoproxil and didanosine were taken together.
Danish: Der er rapporteret om sjældne tilfælde af betændelse i bygspytkirtlen og laktatacidose (overskud af mælkesyre i blodet), der somme tider kan være dødelige, når medicin, der indeholder tenofovirdisoproxil og didanosin, blev indtaget samtidigt.
English: Seroconversions / Nb a ‘Case' = HIV seroconverter; ‘Cohort' = 100 randomly selected subjects from each of the tenofovir disoproxil 245 mg and emtricitabine/tenofovir disoproxil groups.
Danish: a‘Case' = personer med HIV-serokonversion; ‘Kohorte' = 100 tilfældigt udvalgte forsøgspersoner fra hver af tenofovirdisoproxil 245 mg- og emtricitabin/tenofovirdisoproxil-grupperne.
English: Pre-exposure prophylaxis: The iPrEx study (CO-US-104-0288) evaluated emtricitabine/tenofovir disoproxil or placebo in 2,499 HIV-uninfected men (or transgender women) who have sex with men and who were considered at high risk for HIV infection.
Danish: Profylakse før eksponering: iPrEx-studiet (CO−US−104−0288) evaluerede emtricitabin/tenofovirdisoproxil versus placebo hos 2.499 mænd (eller transkønnede kvinder) uden HIV-infektion, der har sex med mænd, og som blev anset for at have høj risiko for HIV-infektion.
English: Treatment of HIV-1 infection: In an open-label randomised clinical study (GS-01-934), antiretroviral-naïve HIV-1 infected adult patients received either a once daily regimen of emtricitabine, tenofovir disoproxil and efavirenz (n = 255) or a fixed combination of lamivudine and zidovudine administered twice daily and efavirenz once daily (n = 254).
Danish: Behandling af HIV 1-infektion: I et åbent, randomiseret, klinisk studie (GS-01-934) fik antiretroviralnaive voksne patienter, inficeret med HIV 1, et regime med enten emtricitabin, tenofovirdisoproxil og efavirenz en gang daglig (n = 255) eller en kombinationsformulering med lamivudin og zidovudin administreret to gange daglig og efavirenz en gang daglig (n = 254).
English: In subjects with end-stage renal disease (ESRD) requiring haemodialysis, between dialysis drug exposures substantially increased over 72 hours to 53 (19%) µg•h/mL of emtricitabine, and over 48 hours to 42,857 (29%) ng•h/mL of tenofovir.
Danish: Hos forsøgspersoner med nyresygdom i slutstadiet (End Stage Renal Disease, ESRD), som havde behov for hæmodialyse, steg lægemiddelkoncentrationen betragteligt imellem dialyserne over et tidsrum på 72 timer til 53 (19%) µg•t/ml og tenofovirs koncentration steg over et tidsrum på 48 timer til 42.857 (29%) ng•t/ml.
English: In study GS US 104 0352, 8 out of 89 paediatric patients (9.0%) exposed to tenofovir disoproxil discontinued study drug due to renal adverse events.
Danish: I studie GS-US-104-0352 fik8 ud af 89 pædiatriske patienter (9,0 %), der blev eksponeret for tenofovirdisoproxil, seponeret studiemedicinen på grund af nyrebivirkninger.
English: • If you are taking Emtricitabine/Tenofovir disoproxil Mylan to reduce the risk of getting HIV, do not stop taking this medicine or miss any doses.
Danish: • Hvis De tager Emtricitabine/Tenofovir disoproxil Mylan for at nedsætte risikoen for at få HIV, må De ikke holde op med at tage medicinen eller springe en dosis over.
English: Age (Yrs), Median (Q1, Q3)
Danish: Alder (år), Median (1. kvartil, 3. kvartil)
English: At week 48, 83% of patients in the tenofovir disoproxil treatment group and 92% of patients in the stavudine or zidovudine treatment group had HIV 1 RNA concentrations < 400 copies/mL.
Danish: I uge 48 havde 83 % af patienterne i gruppen, der fik tenofovirdisoproxil, og 92 % af patienterne i gruppen, der fik stavudin eller zidovudin, koncentrationer af HIV 1-rna på < 400 kopier/ml.
English: Cmin: ↓ 21% (↓ 58 to ↑ 48)
Danish: Cmin: ↓ 21% (↓ 58 til ↑ 48)
English: Lamivudine:
Danish: Lamivudin:
English: angioedema3
Danish: angioødem3